分子分型与乳腺癌新辅助化疗疗效的相关性

目的:探讨乳腺癌分子分型与新辅助化疗疗效的相关性.方法:回顾性分析81例原发乳腺癌患者,分子分型分为HER-2阳性型和三阴型、Luminal A型、Luminal B1型、 Luminal B2型,并评估其与乳腺癌新辅助化疗疗效的关系.结果:新辅助化疗疗效与各分子分型之间的相关性无统计学意义,但新辅助化疗有效率达到pCR+tpCR(%)以三阴型最高(25%),其次是HER-2阳性型(23.1%),而达到CR+PR(%)为HER-2阳性型最高(84.6%).结论:乳腺癌新辅助化疗可有效控制肿瘤,分子分型能作为乳腺癌新辅助化疗疗效的缓解独立预测因子.

Study on relationship between molecular typing and the efficacy of neoadjuvant chemotherapy in breast cancer

Objective:To study the relationship between molecular typing and the efficacy of neoadjuvant chemotherapy in breast cancer.Methods:A retrospective study was conducted in 81 patients with primary breast cancer.Molecular typing is divided into HER-2 positive type and three negative type,Luminal A type,Luminal B1 type,Luminal B2 type,which efficacy with neoadjuvant chemotherapy for breast cancer wes evaluated.Results:There was no significant correlation between the efficacy of neoadjuvant chemotherapy and molecular typing.But in the efficiency of neoadjuvant chemotherapy to pCR+tpCR(%),three negative type was highest(25%),followed by HER-2 positive type(23.1%),while CR+PR(%) was the highest in HER-2 positive type(84.6%).Conclusion:Neoadjuvant chemotherapy for breast cancer can effectively control the tumor.The molecular typing can be used as an independent predictor of neoadjuvant chemotherapy for breast cancer.